The ResApp Health Ltd (ASX:RAP) share price is sinking on Monday after announcing the completion of a $5.5 million capital raising…
The post Why the ResApp (ASX:RAP) share price is down 9% today appeared first on The Motley Fool Australia. –
The ResApp Health Ltd (ASX: RAP) share price has returned from its trading halt and sunk lower.
At the time of writing, the digital health company’s shares are down 9% to 6.2 cents.
Why was the ResApp share price in a trading halt?
ResApp requested a trading halt last week so that it could undertake a capital raising.
This morning the company announced the successful completion of its capital raising after receiving firm commitments from institutional and sophisticated investors to raise $5.5 million before costs.
According to the release, these funds will be raised through the issue of 94,827,588 new fully paid ordinary shares at an issue price of 5.8 cents per share. This represents a 14.7% discount to its last close price.
Its existing substantial shareholder, Fidelity International, has agreed to cornerstone the capital raising with a $1.5 million investment.
Why is ResApp raising funds?
The release advises that the funds raised from the capital raising provide ResApp with the financial flexibility to progress a number of initiatives.
This includes the hiring of key personnel, allowing the company to grow its commercial partnership pipeline and expedite product development initiatives. Funds will also be used for general working capital purposes.
ResApp’s CEO and Managing Director, Dr Tony Keating, said: “We are very pleased to have generated such strong interest in the placement. I would like to welcome a number of new institutional investors to our register and also express our thanks to our existing shareholders who have continued to support the company.”
“Funds secured from the placement will provide ResApp with a very solid footing to execute on our commercial strategy in telehealth and emerging markets, continue to innovate in areas such as COVID19 screening and management, and further expand the opportunity to provide solutions to large pharmaceutical companies for clinical trials and disease management,” he added.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Why Corp Travel Management, IGO, Limeade, & ResApp are tumbling lower
- ASX stock of the day: Why ResApp Heath (ASX:RAP) shares are soaring
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.